about
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialEstablishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.Marine compounds inhibit growth of multiple myeloma in vitro and in vivo11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH.Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.Novel investigational drugs active as single agents in multiple myeloma.Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.Genomic Aberrations in Multiple Myeloma.Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma.Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple MyelomaUsing digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple MyelomaSuppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.The Osteological Paradox 20 Years Later: Past Perspectives, Future DirectionsPharmacological Properties, Molecular Mechanisms, and Pharmaceutical Development of Asiatic Acid: A Pentacyclic Triterpenoid of Therapeutic Promise
P2860
Q28075927-A7350422-5079-4257-A959-53E019A0C8B5Q35636675-39FCC322-B79E-4ABB-ADAF-DEE82DC4FAF8Q35781537-841985A7-D20B-4965-9D9C-BD100A3870BEQ35781619-99168079-0F91-4236-B594-7B584AA2B470Q36053910-B71AFEB6-2329-48FB-BCD3-486503E1C067Q36544069-A236216A-66FC-44BC-BB7E-9D737467B4B7Q37746021-0557CD4A-FB8B-4ECE-B6EB-EB5649308496Q38690290-16E664F1-73DF-4AA5-8A76-849ED3E991AAQ38814114-A9767F00-4CE6-4668-A2A2-0EF4587966CBQ38927463-65200453-3FB5-4B6E-9C40-E412E44C8124Q38970573-D0C1C2CF-D5E6-4F53-95C2-4D7B144CFE2FQ39021977-4087E3AD-B992-411B-BE39-5107F8F0DD0DQ41663752-36D438ED-E21F-46B6-9F51-1142C2D96BEEQ41701047-7D8F881D-642E-4643-8779-197FCDB88024Q41768870-DBD56287-A58E-4AC8-8736-3BB1B272645BQ42055422-3B3530C1-C46A-42E8-8752-28BEC38A6F28Q44175092-41F4FCFC-0A41-40FD-9232-C2A62C30CF36Q46432419-8C932984-61CC-45E9-AB0F-9EEF90F825FCQ49428299-26121402-F367-401C-B727-162AC5EF169AQ49456418-95988D2E-94B4-4FDA-BD55-771FD611DE12Q58294442-2AB2978C-AD99-4975-B776-D1FC61149326Q58764682-FC443AD0-6A86-4C32-A8C1-7DB59786C6D7
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The genetic architecture of multiple myeloma.
@en
The genetic architecture of multiple myeloma.
@nl
type
label
The genetic architecture of multiple myeloma.
@en
The genetic architecture of multiple myeloma.
@nl
prefLabel
The genetic architecture of multiple myeloma.
@en
The genetic architecture of multiple myeloma.
@nl
P2093
P2860
P356
P1476
The genetic architecture of multiple myeloma.
@en
P2093
Emma Conway O'Brien
Steven M Prideaux
Timothy J Chevassut
P2860
P304
P356
10.1155/2014/864058
P577
2014-04-03T00:00:00Z